The earnings call conveyed a positive outlook with significant revenue growth, strategic rebranding, strong partnerships, and financial positioning to support future product launches. However, the company still faces challenges with a notable net loss and uncertain cash burn rate.

Company Guidance

During Dyadic International's Q2 2025 conference call, significant guidance was provided regarding the company's strategic and financial direction. The company reported a total revenue increase to $967,000, a substantial rise from $386,000 in the same period a year ago, driven by milestone and grant revenues. Operational expenses were carefully managed, with a decrease in G&A expenses to $1,437,000 from $1,608,000 the previous year, reflecting reductions in several administrative costs. The net loss for the quarter was reduced to $1,794,000 or $0.06 per share, compared to $2,045,000 or $0.07 per share last year. Dyadic announced a $5.3 million equity raise, strengthening its balance sheet to support late-stage product development and upcoming launches. The company has focused its strategy on high-growth, nontherapeutic markets with its proprietary platforms, C1 and Dapibus, which enable efficient and scalable animal-free protein production. Looking forward, Dyadic anticipates further revenue growth with upcoming milestones and product sales, aiming to achieve cash flow positivity by the end of 2026.

Revenue Growth

Total revenue for the quarter increased to $967,000, up from $386,000 in the same period a year ago, driven by milestone revenue and grant revenue.

Strategic Transformation

Dyadic transitioned from a technology-focused R&D company to a market-facing revenue-driven biotechnology business, rebranding as Dyadic Applied BioSolutions.

Equity Raise

Dyadic strengthened its balance sheet with a $5.3 million equity raise to fund product development and commercialization efforts.

Partnerships and Milestones

Received $1 million in milestone payments from Proliant Health & Biologics and $250,000 from Inzymes for productivity gains. A $1.5 million milestone was triggered by the Gates Foundation grant.

Product Advancements

Advancements in recombinant human albumin, transferrin, and FGFs, with commercial launches and sampling underway. RNase-Free DNase1 production scaled up, with sampling and commercial discussions ongoing.

Dyadic International (DYAI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

DYAI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.03 / -	-0.01	―	―	―
Aug 13, 2025	2025 (Q2)	-0.06 / -0.06	-0.07	14.29% (+0.01)	―
May 14, 2025	2025 (Q1)	- / -0.07	-0.07	0.00% (0.00)	―
Mar 26, 2025	2024 (Q4)	-0.04 / -0.05	-0.08	37.50% (+0.03)	―
Nov 12, 2024	2024 (Q3)	-0.07 / -0.01	-0.06	83.33% (+0.05)	―
Aug 13, 2024	2024 (Q2)	-0.07 / -0.07	-0.07	0.00% (0.00)	―
May 14, 2024	2024 (Q1)	- / -0.07	-0.03	-133.33% (-0.04)	―
Mar 28, 2024	2023 (Q4)	-0.07 / -0.08	-0.07	-14.29% (>-0.01)	―
Nov 08, 2023	2023 (Q3)	-0.06 / -0.06	-0.06	0.00% (0.00)	―
Aug 09, 2023	2023 (Q2)	-0.05 / -0.07	-0.12	41.67% (+0.05)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

DYAI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 13, 2025	$0.82	$0.80	-2.44%
May 14, 2025	$1.04	$1.00	-3.85%
Mar 26, 2025	$1.33	$1.35	+1.50%
Nov 12, 2024	$1.14	$1.12	-1.75%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Dyadic International Inc. (DYAI) report earnings?

Dyadic International Inc. (DYAI) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Dyadic International Inc. (DYAI) earnings time?

Dyadic International Inc. (DYAI) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is DYAI EPS forecast?

DYAI EPS forecast for the fiscal quarter 2025 (Q3) is -0.03.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing